Surreal illustration of liver cancer detection with DNA strands and protein markers

Unlocking Liver Cancer: Can VEGF and AFP Levels Be the Key?

Reese Marlowe in Health & Wellness December 2025 • 5 min read.

"A Deep Dive into How Vascular Endothelial Growth Factor and Alpha-Fetoprotein Could Revolutionize Hepatocellular Carcinoma Detection"

Hepatocellular carcinoma (HCC), a primary liver cancer, stands as a formidable global health challenge. It's recognized as the third leading cause of cancer-related deaths worldwide. The insidious nature of HCC often results in late-stage diagnoses, contributing to its high mortality rate. Early detection is crucial, but current methods often lack the sensitivity needed to identify the disease in its nascent stages. This gap underscores the urgent need for innovative diagnostic tools that can improve patient outcomes.

In the quest for better diagnostic markers, Vascular Endothelial Growth Factor (VEGF) and alpha-fetoprotein (AFP) have emerged as potential candidates. VEGF, known for its role in angiogenesis—the formation of new blood vessels—is pivotal in tumor growth and metastasis. AFP, a protein produced by the liver, is commonly elevated in HCC patients. However, the reliability of AFP as a standalone marker has been questioned, prompting investigations into VEGF and its potential as a complementary or alternative marker.

Recent research has focused on understanding the interplay between VEGF, AFP, and genetic factors in the progression of HCC. A study published in Genetics and Molecular Research investigated the influence of the VEGF-C936T polymorphism—a genetic variation in the VEGF gene—on the prognosis of HCC, cirrhosis, and hepatitis C virus (HCV) infection. The study aimed to determine if this genetic marker, combined with serum levels of VEGF and AFP, could offer a more accurate means of detecting HCC.

Decoding VEGF and AFP: What the Study Reveals

Surreal illustration of liver cancer detection with DNA strands and protein markers

The Genetics and Molecular Research study involved 285 participants, divided into four groups: HCC patients, cirrhosis patients, HCV patients, and a control group without liver disease. Researchers analyzed the prevalence of the VEGF-C936T polymorphism and measured serum levels of VEGF and AFP. The results provided intriguing insights into the diagnostic potential of these markers.

Here’s a breakdown of the key findings:

VEGF-C936T Polymorphism: The study found that the VEGF-C936T polymorphism itself was not directly associated with HCC. However, the presence of the mutant allele (T) was linked to increased VEGF levels in HCC patients.
VEGF Levels: HCC patients exhibited significantly higher VEGF levels compared to those with cirrhosis, HCV, or no liver disease. This suggests that VEGF could serve as a potential biomarker for HCC detection.
AFP Levels: While AFP levels were elevated in HCC patients, they also showed a similar trend in patients with cirrhosis. This indicates that AFP may be more useful in differentiating HCC from HCV or healthy individuals.
Sensitivity and Specificity: VEGF showed a sensitivity of 65% and a specificity of 85% for HCC detection. AFP had a lower sensitivity (28%) but a higher specificity (99%). This underscores the potential of using both markers in conjunction to improve diagnostic accuracy.

The study also explored the correlation between VEGF and AFP levels. While a weak correlation was observed, the researchers noted that combining these markers could enhance diagnostic precision. The receiver operating characteristic (ROC) curve analysis highlighted the discriminatory power of each variable, further supporting their potential as diagnostic tools.

The Future of HCC Detection

The study from Genetics and Molecular Research provides valuable insights into the potential of VEGF and AFP as biomarkers for HCC. While the VEGF-C936T polymorphism alone may not be a reliable marker, the combination of genetic analysis with serum level measurements could pave the way for more accurate and personalized diagnostic strategies. Further research is needed to validate these findings in larger, more diverse populations and to explore the clinical utility of VEGF and AFP in HCC management. As the quest for early detection continues, these findings offer hope for improved patient outcomes in the fight against liver cancer.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.4238/2015.december.21.16, Alternate LINK

Title: Influence Of Vascular Endothelial Growth Factor And Alpha-Fetoprotein On Hepatocellular Carcinoma

Subject: Genetics

Journal: Genetics and Molecular Research

Publisher: Genetics and Molecular Research

Authors: E.Y. Yvamoto, R.F. Ferreira, V. Nogueira, M.A.S. Pinhel, G.D. Tenani, J.G.S.C. Andrade, M.E.L. Baitello, M.L. Gregório, P.S. Fucuta, R.F. Silva, D.R.S. Souza, R.C.M.A. Silva

Published: 2015-01-01

Everything You Need To Know

What is hepatocellular carcinoma (HCC), and why is early detection so important?

Hepatocellular carcinoma (HCC) is a primary liver cancer that poses a significant global health challenge due to its high mortality rate. Early detection is crucial because it allows for timely interventions. The challenge lies in the current diagnostic methods often failing to detect HCC in its early stages, highlighting the need for more sensitive and specific diagnostic tools.

How do Vascular Endothelial Growth Factor (VEGF) and Alpha-fetoprotein (AFP) relate to liver cancer detection?

Vascular Endothelial Growth Factor (VEGF) is a protein that promotes angiogenesis, the formation of new blood vessels, which is crucial for tumor growth and metastasis. Alpha-fetoprotein (AFP) is a protein typically produced by the liver, and elevated levels of AFP often indicate the presence of HCC. The study suggests that the VEGF-C936T polymorphism, a genetic variation in the VEGF gene, combined with serum levels of VEGF and AFP could offer a more accurate means of detecting HCC, thus enhancing diagnostic precision.

What role did the VEGF-C936T polymorphism play in the study, and what were the findings regarding VEGF and AFP levels?

The VEGF-C936T polymorphism, a genetic variation within the VEGF gene, wasn't directly associated with HCC on its own. However, the presence of the mutant allele (T) was linked to increased VEGF levels in HCC patients. These elevated levels of VEGF, which showed a sensitivity of 65% and a specificity of 85%, indicate its potential as a biomarker. AFP, while elevated in HCC patients, also showed similar trends in cirrhosis patients; its use is therefore limited, but it can be used in conjunction with VEGF.

How effective are VEGF and AFP as diagnostic markers for hepatocellular carcinoma (HCC), and why is this significant?

The study found that VEGF and AFP levels could provide valuable insights into the detection of HCC. VEGF showed a sensitivity of 65% and a specificity of 85% for HCC detection, whilst AFP had a lower sensitivity (28%) but a higher specificity (99%). This supports the potential of combining these markers to improve diagnostic accuracy. The use of these markers is important as it can lead to more accurate diagnoses and better patient outcomes. Combining these two markers can enhance the precision with which HCC is diagnosed.

What are the implications of these findings for the future of hepatocellular carcinoma (HCC) detection and patient outcomes?

The study suggests that VEGF and AFP, along with genetic analysis, can potentially lead to more accurate and personalized diagnostic strategies for HCC. Further research is needed to validate these findings in larger populations. If validated, these findings offer hope for improved patient outcomes in the fight against liver cancer because of the ability for earlier and more accurate diagnoses, leading to quicker treatment interventions, and improving the chance of survival.